Cardiovascular disease stands as the leading cause of mortality and morbidity, with more than 523 million individuals affected by the condition. Atherosclerotic cardiovascular disease, especially ischemic heart disease and stroke, contributes to a significant disease burden and poses serious implications for health systems and resource availability. Thus, the rising cases of atherosclerotic cardiovascular disease coupled with the substantial investment in research and development (R&D) by pharmaceutical companies are anticipated to boost the growth of the drug pipeline in the coming years.
Major companies involved in the atherosclerotic cardiovascular disease (ASCVD) treatment market include Amgen, AstraZeneca, and Novartis Pharmaceuticals, among others.
Leading drugs currently under the pipeline include Obicetrapib and Olpasiran, among others.
The increasing prevalence of cardiovascular diseases and the rising advancements in lipid-lowering and anti-inflammatory therapies are poised to positively influence the atherosclerotic cardiovascular disease (ASCVD) pipeline landscape.
The Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into atherosclerotic cardiovascular disease (ASCVD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Atherosclerotic Cardiovascular Disease (ASCVD). The atherosclerotic cardiovascular disease (ASCVD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atherosclerotic cardiovascular disease (ASCVD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with atherosclerotic cardiovascular disease (ASCVD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atherosclerotic cardiovascular disease (ASCVD).
Atherosclerotic cardiovascular disease refers to a chronic condition caused by the buildup of plaque in the walls of arteries, leading to the narrowing of blood flow and consequently reduction in the oxygen supply to the body. Common symptoms include chest pain, weakness, shortness of breath, and pain in the arms or legs, among others. Atherosclerotic cardiovascular disease can start as early as childhood. However, it develops gradually over time and may progress into a heart attack or angina.
Atherosclerotic cardiovascular disease (ASCVD) therapeutics include statins, anticoagulants (or blood thinners), and antiplatelet medicines. Antiplatelet drugs, such as ticlopidine, aspirin, clopidogrel, and dipyridamole, help in decreasing the ability of platelets to stick together, thereby preventing clots. Further, the rising regulatory support for atherosclerotic cardiovascular disease (ASCVD) emerging drugs, including RNA-based and gene therapies, along with the growing aging population, is expected to support the pipeline expansion in the coming years.
Cardiovascular disease affects more than 523 million people worldwide. Various studies reveal atherosclerotic cardiovascular diseases, especially stroke and ischemic heart disease, account for a significant cardiovascular disease burden. It is estimated that ischemic heart disease contributes to around half of the total cardiovascular disease-related deaths, whereas a quarter is attributed to ischemic stroke.
This section of the report covers the analysis of atherosclerotic cardiovascular disease (ASCVD) drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with an estimated 43 atherosclerotic cardiovascular disease (ASCVD) drugs undergoing clinical development.
The drug molecule categories covered under atherosclerotic cardiovascular disease (ASCVD) pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, gene therapies, peptide-based therapies, vaccines, natural product derivatives, and combination therapies. The atherosclerotic cardiovascular disease (ASCVD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atherosclerotic cardiovascular disease (ASCVD).
The EMR report for the atherosclerotic cardiovascular disease (ASCVD) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atherosclerotic cardiovascular disease (ASCVD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in atherosclerotic cardiovascular disease (ASCVD) clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by NewAmsterdam Pharma, the objective of this randomized clinical trial is to investigate the efficacy and safety of the atherosclerotic cardiovascular disease (ASCVD) drug candidate Obicetrapib in patients who didn’t show adequate response to maximally tolerated lipid-lowering therapy. The study is under Phase III clinical development and has an estimated 9541 participants.
Amgen is conducting a Phase III study aimed at examining the efficacy of the investigational drug Olpasiran on the risk for myocardial infarction, coronary heart disease death, or urgent coronary revascularization in patients with atherosclerotic cardiovascular disease and elevated Lipoprotein(a). The interventional study has enrolled about 7297 subjects and is expected to be completed by December 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Atherosclerotic Cardiovascular Disease (ASCVD) Drug Report provides a strategic overview of the latest and future landscape of treatments for atherosclerotic cardiovascular disease (ASCVD). it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within atherosclerotic cardiovascular disease (ASCVD) pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share